DelveInsights, “Insight into the Rheumatoid Arthritis pipeline, 2022,” the report provides in-depth insights into 120+ companies and 120+ pipeline drugs in the Rheumatoid Arthritis (RA) pipeline landscape. It covers the pipeline drug profiles, including both clinical and non-clinical stage products. It also includes therapeutic evaluation by product type, stage, route of administration and molecule type. It also highlights the inactive pipeline products in this space.

Key Findings from the Rheumatoid Arthritis Pipeline Report

• DelveInsight’s Rheumatoid Arthritis Pipeline report shows a robust space with 120+ active players working to develop 120+ pipeline therapies for Rheumatoid Arthritis.
• The leading rheumatoid arthritis companies such as Abivax, Kymera Therapeutics, Akari Therapeutics, Sierra Oncology, Neutrolis Therapeutics, Centivax, Taisho, Hope Biosciences, UCB, Galmed Pharmaceuticals, Celon Pharma, Jiangsu Hengrui Medicine Co., Cyxone, Oryn Therapeutics and others.
• Promising pipeline therapies for rheumatoid arthritis such as M2951, Etanercept, M2591 25mg QD, Mavrilimumab 30mg, Adalimumab, Methotrexate and others.
• The companies and scientists are working to assess challenges and seek opportunities that could impact research and development in rheumatoid arthritis. Therapies under development focus on novel approaches to treat/improve rheumatoid arthritis.
• The report provides a detailed description of the drug, including the drug’s mechanism of action, clinical trials, NDA approvals (if any), and product development activities including the technology, rheumatoid arthritis collaborations, licensing, mergers and acquisitions, financing, designations, and other product-related details.

Get an overview of the Rheumatoid Arthritis pipeline landscape @ New therapies for rheumatoid arthritis

Overview of Rheumatoid Arthritis

Rheumatoid arthritis is known as an autoimmune disease. It starts when your immune system, which is supposed to protect you, goes awry…